Overview
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
Eligibility
Inclusion Criteria:
- Stage IA2-II non-small cell cancer patients who after complete resection.
- Two-round MRD tests confirm landmark undetectable MRD
- Expected survival ≥24 months
- ECOG PS 0-1
- Willing to accept MRD monitoring every 3 months for a total of 2 years after surgery
Exclusion Criteria:
- Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy
- Patients with a history of other malignancies in the past 5 years
- Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.) or other conditions that investigators considered would limit the ability of the patient to participate in the study
